Methods for treating hypophosphatemic disorders
The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
1. A method of treating a hypophosphatemic disorder associated with abnormal fibroblast growth factor 23 (FGF23) levels and/or activity, comprising administering to a subject in need of such treatment an effective amount of an anti-FGF23 antibody, wherein the anti-FGF23 antibody is administered about every two weeks, and wherein the anti-FGF23 antibody comprises the CDR sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.
2. The method of claim 1 , wherein the hypophosphatemic disorder is selected from the group consisting of autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemic rickets (ARHR), fibrous dysplasia (FD), McCune-Albright syndrome complicated by fibrous dysplasia (MAS/FD), Jansen's metaphyseal chondrodysplasia (Jansen's Syndrome), autosomal dominant polycystic kidney disease (ADPKD), tumor-induced osteomalacia (TIO), and chronic metabolic acidosis.
3. The method of claim 1 , wherein the hypophosphatemic disorder is XLH.
4. The method of claim 1 , wherein the hypophosphatemic disorder is TIO.
5. The method of claim 1 , wherein the heavy chain of the anti-FGF23 antibody comprises a sequence of SEQ ID NO: 7.
6. The method of claim 1 , wherein the light chain of the anti-FGF23 antibody comprises a sequence of SEQ ID NO: 8.
7. The method of claim 1 , wherein the heavy chain of the anti-FGF23 antibody comprises a sequence of SEQ ID NO: 7 and the light chain of the anti-FGF23 antibody comprises a sequence of SEQ ID NO: 8.
8. The method of claim 1 , wherein the anti-FGF23 antibody is administered parenterally, subcutaneously, intravenously, intramuscularly, or intraperitoneally.
9. The method of claim 8 , wherein the anti-FGF23 antibody is administered subcutaneously.
10. The method of claim 1 , wherein the anti-FGF23 antibody is administered with a pharmaceutically-acceptable carrier.
11. The method of claim 1 , wherein the subject is a human.
12. The method of claim 11 , wherein the subject is a pediatric subject.
13. The method of claim 1 , wherein the anti-FGF23 antibody is administered at a dose of about 0.8 mg/kg.
14. The method of claim 1 , wherein the anti-FGF23 antibody is administered at a dose of about 1.0 mg/kg.